Bml Capital Management, LLC Metacrine, Inc. Transaction History

Bml Capital Management, LLC

  • $170 Billion
  • Q3 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 13, 2023
BUY
$0.35 - $0.46 $2.16 Million - $2.84 Million
6,167,458 New
6,167,458 $2.76 Billion

Others Institutions Holding MTCR

# of Institutions
1
Shares Held
0
Call Options Held
0
Put Options Held
0
View Full List

About Metacrine, Inc.

MTCR Quotes by TradingView
  • Ticker MTCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,569,500
  • Description
  • Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
More about MTCR
Track This Portfolio

Track Bml Capital Management, LLC Portfolio

Follow Bml Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bml Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bml Capital Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email